Title21 Health Solutions Acquires MyCellHub

ARCHIMED Acquires Majority Stake in Title21 Health Solutions

July 12, 2022

Healthcare Services

ARCHIMED has acquired a majority stake in Phoenix-based Title21 Health Solutions through its MED III fund, with founders Lynn Fischer and Kent Kirimli retaining a significant minority. Title21 is an end-to-end software provider for cell and gene therapy labs; ARCHIMED plans to accelerate R&D, international expansion (Europe and Asia) and further digitization of the sector.

Bio-Techne Acquires Namocell

June 22, 2022

Medical Devices

Bio-Techne Corporation has agreed to acquire Namocell, Inc., a Mountain View–based provider of single-cell sorting and dispensing platforms, with the deal expected to close in Bio-Techne's fiscal 2023 Q1. Namocell's Pala and Hana systems (installed base approaching 200 placements, ~60 sold in 2021) will complement Bio-Techne's Cell and Gene Therapy franchise and create commercial synergies across its analytical instruments sales force.

StatLab Medical Products Acquires CellPath Ltd.

June 8, 2022

Medical Devices

StatLab Medical Products, a portfolio company of Audax Private Equity and Linden Capital Partners, acquired UK-based CellPath Ltd., a manufacturer and supplier focused on the histology and cytology markets. The deal adds injection-molding manufacturing capabilities, proprietary products (including the CellNass archiving service), and an established European customer base to support StatLab's international growth.

Myonex Acquires Hubertus Apotheke Clinical Trial and Packaging Business

October 5, 2022

Healthcare Services

Myonex has completed the acquisition of the clinical trial and packaging business of Hubertus Apotheke in Berlin, Germany. The deal creates Myonex GmbH, expanding Myonex’s EU footprint and strengthening its packaging, labeling and sourcing capabilities to support clinical trials across the European Union.

ARCHIMED Acquires Majority Stake in Cellese

April 9, 2024

Consumer Products

Global healthcare private equity firm ARCHIMED has acquired a majority stake in Cellese, the Irvine, California–based developer of growth factor- and exosome-based dermo-cosmetic products sold under the AnteAGE brand. ARCHIMED will support Cellese's commercialization and international expansion while founder Ian Sanderson and his family roll a meaningful portion of proceeds into a minority stake.

ARCHIMED Acquires Majority Stake in ExcellGene and Magellan Biologics

September 25, 2025

Biotechnology

ARCHIMED, a healthcare-focused private equity firm, has acquired a majority stake in Switzerland-based ExcellGene SA and its sister company Magellan Biologics & Consulting (Portugal), partnering with founders Florian and Maria Wurm and management. The investment creates a group focused on cell line development, gene transfer and cell culture-based manufacturing to accelerate work on biosimilars, recombinant proteins and transfection/media products.